8 hospitalized after carbon monoxide leak at Google’s NYC office building

 Eight people were hospitalized after a carbon monoxide leak at a Manhattan office building that includes Google offices, officials said.

FDNY responded to reports of elevated carbon monoxide readings on the upper floors of the commercial building at 85 10th Ave. in Chelsea around 4:30 p.m. on Saturday.

Eight patients were transported to area hospitals in unknown conditions. At least five patients showed symptoms for carbon monoxide poisoning, sources said.

Eight people were hospitalized after a carbon monoxide leak at Google’s office in Manhattan Saturday.

L2FTV contributor for FNTV

FDNY responded to a carbon monoxide leak at a Google office building on Saturday

L2FTV contributor for FNTV

It’s not clear if those affected were Google employees.

Firefighters “ventilated and mitigated the source of leak,” and the incident is under control, FDNY said.

The cause of the leak was not immediately available.

https://nypost.com/2022/07/30/8-hospitalized-after-carbon-monoxide-leak-at-googles-nyc-office-building/

Icosavax Shifts Focus On Bivalent Plan For COVID Vax After Antigen Instability Issues

 

• Icosavax Inc 
  ICVX-9.33%+ Free Alerts
   announced the results of an end-to-end drug product investigation of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD). 
• The investigation followed the company's Phase 1/2 topline interim data results. 
• The immunologic response observed for IVX-411 was inconsistent with expectations based on known data for the company's platform and VLP technology.
• The investigation involved a review of in vitro antigen stability and characterization and in vivo potency, as well as a review of data and protocols relating to the transport, storage, and administration.
• Also Read: Icosavax Shares Plummet Following Interim Results From Initial-Stage RSV Vaccine Study.
• Results of the investigation confirmed the company's initial hypothesis that the reduced potency observed for IVX-411 was antigen-specific.
• No similar pattern of instability has been seen in data to date in other Icosavax vaccine candidates, including for RSV and hMPV.
• The company now focuses on a bivalent strategy for COVID-19 candidate development displaying computationally engineered RBD antigens. Candidate selection is expected in 2023.

https://www.benzinga.com/general/biotech/22/07/28262660/icosavax-shifts-focus-on-bivalent-strategy-for-covid-19-vaccine-candidate-after-antigen-instabili

Novo Nordisk Once-Weekly Insulin Hits Primary Goals In In Two Phase 3 Trials

 

• Novo Nordisk A/S 
  NVO-0.28%+ Free Alerts
   announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes.
• In ONWARDS 3 study, after 26 weeks of treatment, hemoglobin A1c, a measure of blood sugar, had fallen 1.57% from a baseline of 8.5% in the insulin icodec cohort, compared to a 1.36% reduction in the control group. 
• Related: Novo Nordisk's Once-Weekly Insulin Icodec Shows Favorable Reduction In HbA1c In Type 2 Diabetes.
• Novo saw no statistically significant difference in severe or clinically significant hypoglycemia, although the rate was numerically higher in the insulin icodec group. 
• The firm said the drug appeared safe and well tolerated. 
• In ONWARDS 4 study, after 26 weeks, hemoglobin A1c had fallen 1.16% from a baseline of 8.3% in the insulin icodec cohort, compared to a 1.18% reduction in the control group.
• Novo now has data from five of the six phase 3 ONWARDS program trials. Top-line results from the remaining study, ONWARDS 5, are due by the end of the year.

https://www.benzinga.com/general/biotech/22/07/28270518/novo-nordisk-once-weekly-insulin-hits-primary-goals-in-in-two-phase-3-trials